Oliver Sartor

Nov 12, 2024 | urologytimes.com | Oliver Sartor

OpinionVideoNovember 12, 2024Author(s): Gallium PSMA-11 gozetotide is effective in detecting prostate cancer metastases and assessing biochemical recurrence with high sensitivity and specificity. The tracer is particularly useful for identifying small lesions and lymph node involvement in prostate cancer patients. Its utility is limited in cases of low PSMA expression, such as neuroendocrine prostate cancers or heavily treated tumors.

Oct 29, 2024 | urologytimes.com | Oliver Sartor

OpinionVideoOctober 29, 2024Author(s): 68gallium PSMA-11 gozetotide is essential for prostate cancer imaging but faces production and distribution challenges. Expanding production facilities and streamlining regulatory processes could enhance availability. Collaborations between academic institutions and industry may help overcome current limitations. Research into alternative radiotracers or efficient production methods could improve access.

Oct 22, 2024 | urologytimes.com | Oliver Sartor

The panelist discusses how 68gallium prostate-specific membrane antigen-11 (PSMA-11) gozetotide is most useful in PET-CT imaging for detecting and staging prostate cancer. In what situations would you use 68gallium prostate-specific membrane antigen-11 gozetotide in PET-CT imaging? In what situations would this tracer be less useful?

Oct 15, 2024 | urologytimes.com | Oliver Sartor

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential radioligand therapy, considering factors such as disease progression, previous treatments, and overall health status in tailoring management strategies.

Oct 9, 2024 | urotoday.com | Oliver Sartor

Zach Klaassen: Hi, my name is Zach Klaassen. I'm a urological oncologist at the Georgia Cancer Center. Welcome to ESMO 2024, Prostate Cancer Insights on UroToday. I am delighted to be joined for discussion with Dr. Oliver Sartor, who is a medical oncologist at Mayo Clinic in Rochester, Minnesota. Oliver, thanks so much for joining us today. Oliver Sartor: Oh, delighted to do this, Zach. Looking forward to the discussion. Zach Klaassen: It was a historic ESMO for many reasons.